Integra LifeSciences commenced full commercial launch of the Cadence® Total Ankle in Canada, the U.S. and select EU regions.
Since initial clinical use in 2Q16, >200 Cadence procedures have been performed in seven countries. Key features of Cadence include side-specific anatomical tibial and talar components, as well as highly crosslinked UHMWPE bearing insert components and patent pending biased sagittal profile options to address patients with subluxed talar anatomy.
Global postmarket clinical studies are slated to further support product efficacy.
Integra LifeSciences commenced full commercial launch of the Cadence® Total Ankle in Canada, the U.S. and select EU regions.
Since initial clinical use in 2Q16, >200 Cadence procedures have been performed in seven countries. Key features of Cadence include side-specific anatomical tibial and talar components, as well as highly crosslinked...
Integra LifeSciences commenced full commercial launch of the Cadence® Total Ankle in Canada, the U.S. and select EU regions.
Since initial clinical use in 2Q16, >200 Cadence procedures have been performed in seven countries. Key features of Cadence include side-specific anatomical tibial and talar components, as well as highly crosslinked UHMWPE bearing insert components and patent pending biased sagittal profile options to address patients with subluxed talar anatomy.
Global postmarket clinical studies are slated to further support product efficacy.
Copy to clipboard 
